Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Oncolytics Biotech^® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency ("EMA") has granted Orphan Drug Designation for its lead product candidate, REOLYSIN^®, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.

"This is the second jurisdiction where we have gained Orphan Designation for the use of REOLYSIN^® in the treatment of these gynecological cancers and our first grant in the European Union," said Dr. Brad Thompson, President and CEO of Oncolytics. "We continue to secure Orphan Drug Designation for selected cancers as a way to support further development of REOLYSIN^® in key jurisdictions globally."

SOURCE Oncolytics Biotech Inc.